AI BioInsights Hub

AI drug discovery creates a clear legal split: Insilico Medicine publicly credited generative AI for proposing a pulmonary fibrosis molecule, yet its...

A UC San Diego team trained a machine learning model on ~500,000 DNA variants to decode the initiator sequence, revealing it controls transcription...

• Researchers recast molecular docking as a maximum vertex-weighted clique graph problem, converting binding pose searches into finding the densest...

An industry network survey shows AI & Machine Learning now leads as the technology expected to impact healthcare most over the next decade.

Key...

AI generates molecules rapidly yet fails because it recognizes patterns, not biological mechanisms.

• Data bias trap: Models inherit selection biases...

AI adoption in healthcare shows strong momentum but uneven progress.

• Market growth: Global AI healthcare market hits $50.7B in 2026, projected to...

Leading experts from academia and industry will convene to explore how agentic AI and robotics are transforming biomedical research for Alzheimer's disease and related dementias.

AI agents now gather dispersed evidence from papers, patents, and filings to predict trial success probabilities, outperforming baselines on...

OpenBind's first predictive AI model, released with paired experimental protein-ligand data, demonstrates how open resources enable realistic...

Only three of 1,357 FDA-authorized AI medical devices have been evaluated for patient-centered clinical outcomes like mortality or readmissions. This exposes a profound gap between regulatory clearance and real-world validation.

AI is redefining hematopoietic stem cell research by serving as a computational guide to stemness biology. This approach provides students a clear window into how machine learning decodes cell fate in genomics and cell biology.

Machine learning models leveraging multimodal data identify patient subpopulations that benefit from adding tremelimumab to first-line treatment. This approach exemplifies AI-driven precision medicine by matching therapies to responsive groups.

Machine learning integrated with metabolomics has emerged as a promising strategy to advance precision pharmacotherapy, enabling data-driven prediction.

Major pharma firms are accelerating AI-native R&D through a dual approach of external partnerships and high-profile talent acquisition.

• Eli Lilly...

AI is rewriting the clinical trial playbook.

AI is advancing precision oncology in genitourinary cancers through targeted tools:

• LLMs handle documentation, chart summarization, and clinical...

AI is transforming topical drug delivery via permeability modeling, generative design, and personalized formulations amid surging investment.

• $3.3B...

AI paired with spatial proteomics and transcriptomics is uncovering disease mechanisms at single-cell resolution across conditions.

• In melanoma, AI...

Three AI strands are converging to cut costs and risks across drug pipelines:

• Knowledge extraction tools like Causaly mine literature for targets...

AI minibinder workflows deliver target-specific binders via RFdiffusion and screening, yet many fail CAR expression without pI optimization beyond the...